Equity Profile

VKTX

Viking Therapeutics, Inc.

Health CareBiotechnology$4.4B

Apr29Wed

Post-Earnings Recap

ReportedQ1-2026After Close4:05 PM EDT

Viking Therapeutics Misses on EPS, Stock Down 3.27%

Metric	Actual	Expected	Surprise
EPS	$-1.37	$-0.91	-44.51%
Revenue	N/A	$0M	N/A

management commentary, guidance changes, and full analysis available with Pro.

Viking Therapeutics Misses on EPS, Stock Down 3.27%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-1.37	$-0.91	-44.51%
Revenue	N/A	$0M	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Viking Therapeutics reported a larger-than-expected loss per share, which contributed to a 3.27% decline in its stock price. The lack of revenue and guidance further adds uncertainty for investors. Overall, the disappointing EPS results may raise concerns about the company's financial health moving forward.

Company Snapshot

Viking Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metabolic and endocrine disorders....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and financial health, which investors closely monitor.

$-0.91

Revenue

While no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Viking Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metabolic and endocrine disorders. With a market cap of $4 billion, its work is significant as it addresses unmet medical needs in the health care sector, particularly in the treatment of conditions like obesity and diabetes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-19.44%

Avg Stock Reaction

-0.60%

Last Quarter Recap

In the last quarter, Viking Therapeutics reported an EPS of $-1.38, missing the estimate of $-0.89. The stock reacted negatively, declining by 0.70% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Viking to report a loss this quarter, with a consensus EPS of $-0.91. Given the company's history of missing earnings expectations, there is a cautious sentiment among investors.

Bull Case

If Viking can narrow its losses significantly or provide positive updates on its drug pipeline, it could boost investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company reports a larger loss than expected or fails to provide any new insights into its future revenue potential, it could lead to further declines in the stock price.

Key Metrics to Watch

EPS

$-0.91

Earnings per share (EPS) is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$0M

While no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Viking provide any updates on its drug pipeline that could signal future revenue potential?

Investors are keen to understand how the company plans to generate revenue, especially given the lack of expected revenue this quarter.

How does Viking plan to address its ongoing losses, and what steps are being taken to improve profitability?

Management's response to profitability concerns will be critical for investor confidence and could influence stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly pessimistic about Viking's potential for revenue generation, especially if there are positive developments in its drug pipeline that have not been fully accounted for.

Supporting Evidence

The options market is pricing in an 8.67% move, indicating expectations of volatility that may not align with the actual performance.

Viking's historical performance shows a tendency to surprise on the upside, even when consensus is cautious.

Key Risk

If Viking provides any positive updates on its drug pipeline or plans for future revenue, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to manage its losses and provide a clear path to future profitability.

Bull Confirmed If

A narrower loss than the consensus estimate of $-0.91 could confirm a more optimistic outlook.

Bear Confirmed If

A larger loss than expected, particularly if it exceeds $-1.43, would reinforce bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±8.67%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±8.5% while VKTX has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.4%

30d HV

53.3%

Calls (458K)P/C Ratio: 0.60Puts (88K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 11 of 25 (44%)

This setup has occurred 30 times across Health Care in the last 2 years. 11 of 25 faded and 14 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.3%, with a raw directional average of +2.3% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Viking beats expectations and narrows its losses, history suggests the stock could rise by an average of 1.54% the next day.

In-Line / Cautious

If results are in line with expectations, management's commentary could lead to a muted response, reflecting cautious sentiment.

Miss

If the company misses expectations, history suggests a potential decline of about 0.67% the following day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug pipeline and any potential revenue streams.
2Management's strategy for addressing ongoing losses.
3Any guidance on future profitability or milestones.
4Responses to analyst questions regarding competitive positioning.
5Insights into market conditions affecting the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

OMABReported

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.

RecapView

Apr27

PIIReported

Company Snapshot

Viking Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metabolic and endocrine disorders....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and financial health, which investors closely monitor.

$-0.91

Revenue

While no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-19.44%

Avg Stock Reaction

-0.60%

Last Quarter Recap

In the last quarter, Viking Therapeutics reported an EPS of $-1.38, missing the estimate of $-0.89. The stock reacted negatively, declining by 0.70% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Viking to report a loss this quarter, with a consensus EPS of $-0.91. Given the company's history of missing earnings expectations, there is a cautious sentiment among investors.

Bull Case

If Viking can narrow its losses significantly or provide positive updates on its drug pipeline, it could boost investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company reports a larger loss than expected or fails to provide any new insights into its future revenue potential, it could lead to further declines in the stock price.

Key Metrics to Watch

EPS

$-0.91

Earnings per share (EPS) is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$0M

While no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Viking provide any updates on its drug pipeline that could signal future revenue potential?

Investors are keen to understand how the company plans to generate revenue, especially given the lack of expected revenue this quarter.

How does Viking plan to address its ongoing losses, and what steps are being taken to improve profitability?

Management's response to profitability concerns will be critical for investor confidence and could influence stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly pessimistic about Viking's potential for revenue generation, especially if there are positive developments in its drug pipeline that have not been fully accounted for.

Supporting Evidence

The options market is pricing in an 8.67% move, indicating expectations of volatility that may not align with the actual performance.

Viking's historical performance shows a tendency to surprise on the upside, even when consensus is cautious.

Key Risk

If Viking provides any positive updates on its drug pipeline or plans for future revenue, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to manage its losses and provide a clear path to future profitability.

Bull Confirmed If

A narrower loss than the consensus estimate of $-0.91 could confirm a more optimistic outlook.

Bear Confirmed If

A larger loss than expected, particularly if it exceeds $-1.43, would reinforce bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±8.67%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±8.5% while VKTX has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.4%

30d HV

53.3%

Calls (458K)P/C Ratio: 0.60Puts (88K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 11 of 25 (44%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Viking beats expectations and narrows its losses, history suggests the stock could rise by an average of 1.54% the next day.

In-Line / Cautious

If results are in line with expectations, management's commentary could lead to a muted response, reflecting cautious sentiment.

Miss

If the company misses expectations, history suggests a potential decline of about 0.67% the following day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug pipeline and any potential revenue streams.
2Management's strategy for addressing ongoing losses.
3Any guidance on future profitability or milestones.
4Responses to analyst questions regarding competitive positioning.
5Insights into market conditions affecting the biotechnology sector.